Page 223 - Read Online
P. 223

dos Santos et al. J Cancer Metastasis Treat 2019;5:25  I  http://dx.doi.org/10.20517/2394-4722.2018.83                  Page 15 of 20

               Cholangiocarcinoma             Porfimer sodium  Observational  30/Dec/18  200   NCT01524146
               Esophageal Adenocarcinoma, Early  any           Observational  Jan/22    400    NCT00587314
               Lung Cancer                    Porfimer sodium  Observational  30/Dec/24  1000  NCT01842555
               Lung Cancer                    any              Observational  15/Dec/23  1000  NCT03589456
               Neoplastic Disease             any              Observational  Jul/21    400    NCT02159742
               Prostate Cancer                any              Observational  01/Mar/20  200   NCT03492424
               *HPPH stands for 2-1[Heyloxyethyl]-2-Devinylpyropheophorbide-a


               photodynamic cell death by necrosis and selective time- and dose dependent phototoxic effects on MCF-7
               cells but little damage to non-tumorigenic cells. The micelles inhibited the generation of cellular colonies as
               well as migration of tumor cells indicating possible capacity to prevent the recurrence of breast cancer and
               to minimize the chances of cell spreading and thus the formation of metastases [129] .

               Although PDT is based on the preferential accumulation in the tumor tissue, this selectivity is not absolute
               and some damage can occur to the surrounding tissue. Thus, a deeper understanding of the molecular
               mechanisms involved in drug delivery and specific targeting of tumors should contribute to the development
               of more specific technologies to deliver light and/or drugs to the tumor site and also to minimize resistance
               to PDT. Accordingly, the development of new PS targeting specific tumor sites have led to the modality of
                           [130]
               targeted-PDT . Another approach consists the photochemical delivery of drugs through photochemical
               internalization (PCI), a modified form of PDT. PCI is actually a light-controlled drug-delivery alternative in
               which light activation enables spatiotemporal specificity and control of the intracellular drug release [131-133] .
               Moreover the potential of PCI to circumvent the resistance and increase the efficacy of a variety of
               anticancer agents, have been demonstrated in several tumor models including approaches to overcome PDT-
               resistance in breast cancer cells [133,134] . Since identifying cellular resistance mechanisms by understanding the
               differences in cell response at the molecular level is of fundamental importance to improving the protocol
               and to increase the success of the therapy [135] , we have recently shown that breast cancer cells are differently
               affected by methylene blue (MB) concentrations at the same light dose in MB-PDT and that non-malignant
                                                                                                   [26]
               human breast cells are significantly more resistant to the therapy compared to the malignant ones . One
               more example of how the use of a targeting agent would ideally improve the selectivity of PDT for the
               tumor tissue has been shown in a recent study. By using polyethylene glycol-coated, folate conjugated,
               benzoporphyrin derivative-loaded liposomes for PDT treatment of breast cancer cells, the researchers have
               reported that these liposomes are targeted for are greater uptake into TNBC cancer cells [136] . Therefore,
               focusing on the molecular differences of cell death mechanisms induced by PDT, starting with an optimized
               PS choice and conditions of its delivery and activation, will certainly provide valuable clues for the
               development of new therapeutic strategies aiming at improving the efficacy of PDT against cancer cells [7,15] .



               CONCLUSION
               The challenges in fighting the disease rely on intrinsic tumor resistance properties, molecular heterogeneity,
               and metastasis. Considering all the information provided one can conclude that there are almost no doubts
               that one relevant advantage of PDT over other cancer treatments is the possibility of generating less side
               effects to the patients.

               In summary, in this review we have explored and presented a broad up-date on the use of PDT as a
               therapeutic approach in the treatment of primary cancer as well as metastasis. We have covered several
               topics ranging from the photochemical mechanisms involved, the different cell death mechanisms being
               triggered by several photosensitizers up to the more recent-on-going clinical trials. Additionally, we
               have presented a significant amount of information underscoring the relevance of PDT as an alternative
               therapeutic approach capable of inducing several mechanisms of cell death, some of them simultaneously.
   218   219   220   221   222   223   224   225   226   227   228